Biology subjects

Kozielewicz, P.

Publications and source records attributed to Kozielewicz, P..

8 recordsLinked to original sources

bioRxiv2026

Targeting the Tumor-Stroma Crosstalk: An AI-Based Virtual Screening Strategy for Dual MET/SMO Inhibitors in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by a dense desmoplastic tumor microenvironment (TME) that limits drug penetration and promotes immune evasion. Effective treatment, therefore, requires simultaneous modulation of multiple signaling pathways. Here, we describe a directed polypharmacological strategy to identify dual modulators of c-MET and Smoothened (SMO), aiming to disrupt the protective stroma through SMO inhibition while directly suppressing tumor cell survival via c-MET targeting. An AI-guided virtual screening workflow combining the machine-learning platform PyRMD, trained on known c-MET and SMO ligands, with structure-based molecular docking was applied to a library of over 9 million compounds. This approach led to the identification of compound 21, an aminopyrimidine-benzamide-phenoxyquinoline derivative, as a dual c-MET/SMO inhibitor. Biochemical and cellular studies demonstrated that compound 21 selectively binds the SMO orthosteric site (pKi = 5.60), inhibits agonist-induced GLI (Glioma-associated oncogene) signaling (pIC50 = 5.50), and potently suppresses c-MET kinase activity (pIC50 = 6.94). Western blot analyses further revealed that compound 21 promotes ubiquitin-proteasome-mediated degradation of c-MET, eliminating receptor availability and limiting compensatory resistance signaling. In 3D heterotypic models comprising MIAPaCa2 pancreatic cancer cells and CAF154-hTERT fibroblasts, dual inhibition of SMO-mediated stromal support and c-MET-driven tumor progression resulted in greater cytotoxicity than the combination of the selective inhibitors Sonidegib and PHA-665752. Overall, compound 21 overcomes stromal-mediated resistance, enhances tumor cell death, and validates dual SMO/c-MET targeting as a promising single-agent therapeutic strategy for PDAC. One Sentence SummaryAn AI-identified dual SMO/c-MET inhibitor overcomes stromal resistance and degrades c-MET to suppress pancreatic cancer.

cancer biology↗

bioRxiv2026

Who's driving? Common evolutionary mechanism of activation of class A GPCRs

Cells communicate with their environment by integrating signals, often chemical in nature, triggered by specific molecules bind to specific membrane-bound receptors, resulting in a downstream signaling cascade. Arguably, Gprotein-coupled receptors (GPCRs) constitute the most pharmacologically important family of such receptors, binding small molecules, peptides, lipids, and hormones with high specificity. However, despite a highly conserved fold and sequence similarity, GPCRs are still mostly studied on a case-by-case basis. Here, we infer a general, evolutionarily conserved mechanism of class A GPCR activation. By leveraging coevolution and machine learning methods applied to all class A GPCRs structures, we derive a mathematical description (a so-called collective variable - CV) of the receptors activation state which is independent of its sequence. Then, we bias molecular dynamics simulations along this CV to obtain transitions between activation states of a diverse set of class A GPCR family members. To demonstrate that our model generalizes beyond GPCRs in our training set, we obtain conformational transitions of an orphan receptor, GPR183. Finally, we show that we can model ligand effect on the receptors by converging Free Energy Surfaces of activation of the {beta}2-adrenergic receptor within this common mechanism framework. These results, to our knowledge, prove for the first time the existence of a mechanism uniting all class A GPCRs. Our approach thus facilitates direct comparisons between receptors and opens up the possibility of structural and dynamical studies of many orphan and understudied GPCRs. It also serves as a blueprint for inferring family-wide protein mechanisms.

biophysics↗

bioRxiv2026

Decoding the Structural and Functional Impact of the Leukaemia-Associated A338V Mutation in GPR183

G protein-coupled receptors rely on dynamic conformational changes to coordinate G protein activation and recruitment of regulatory transducers such as G protein-coupled receptor kinases and {beta}-arrestins. The chemotactic receptor GPR183 has been implicated in a context-dependent role in hematological malignancies. Here, we investigated the impact of A338V mutation located within the C-terminal tail of GPR183. This mutation is associated with acute myeloid leukaemia. Using bioluminescence resonance energy transfer-based assays in HEK293A cells, we assessed receptor-proximal signaling events. The A338V variant displayed preserved agonist potency and comparable agonist-induced Gi activation relative to wild type, although constitutive activity towards Gi was modestly reduced. In contrast, recruitment of GRK2 and {beta}-arrestin2 was consistently impaired across multiple assay configurations. These differences were not attributable to altered receptor abundance, as the C-tail untagged mutant exhibited increased plasma membrane expression despite reduced regulatory transducer engagement. While intramolecular conformational biosensor measurements revealed subtle differences in global receptor conformation between WT and A338V, extensive molecular dynamics simulations supported the altered conformational sampling of the C-terminal tail in the A338V variant. Together, these data support a model in which the A338V substitution selectively alters C-terminal structural dynamics, impairing GRK2 and {beta}-arrestin2 recruitment while preserving G protein activation.

pharmacology and toxicology↗

bioRxiv2025

AI-Driven Virtual Screening and First-in-Class Conformational Biosensor Enable the Discovery of a GPR183 Inverse Agonist

GPR183 is a chemotactic G protein-coupled receptor implicated in immune cell migration and various diseases. Here, we report the discovery of novel GPR183 inverse agonists using an artificial intelligence-driven virtual screening approach combined with biophysical sensors including a first-in-class conformational biosensor. From an initial screen of 70 compounds and a hit expansion, a selected candidate - compound 78 - demonstrated potent inhibition of GPR183s constitutive and agonist-stimulated Gi activation as well {beta}-arrestin2 recruitment. The binding of the compound to the receptor core was confirmed by studies using a new conformational sensor based on intramolecular BRET, molecular dynamics, and site-directed mutagenesis experiments. Finally, the compound 78 was able to block agonist-induced migration of peripheral blood mononuclear cells ex vivo. This work provides a novel chemical scaffold for GPR183 modulation. It introduces a new tool for dissecting receptor function, paving the way for therapeutic exploration in inflammatory, autoimmune, and neoplastic disorders.

pharmacology and toxicology↗

bioRxiv2022

WNT stimulation induced conformational dynamics in the Frizzled-Dishevelled interaction

Frizzleds (FZD1-10) are G protein-coupled receptors containing an extracellular cysteine-rich-domain (CRD) that presents the orthosteric binding site of the 19 mammalian WNTs, the endogenous agonists of FZDs. FZDs signal via a diverse set of effector proteins, of which Dishevelled (DVL1-3) is the most well studied and which acts as a hub for several FZD-mediated signaling pathways. However, the mechanistic details of how FZD-DVL interaction mediate pathway initiation and provide pathway selectivity remain an enigma. Here, we use bioluminescence resonance energy transfer-based assays employing Venus-tagged DVL2 together with NanoLuciferase-tagged FZD5 to investigate the WNT-3A- and WNT-5A-induced dynamics of the FZD-DVL interaction. Our biophysical assessment suggests that the ligand-induced BRET changes over time originate from conformational dynamics in the FZD5-DVL2 complex rather than recruitment dynamics of DVL2 to FZD5. Thus, we suggest that extracellular agonist and intracellular transducers could cooperate with each other through allosteric interaction with FZDs in a ternary complex reminiscent of that of classical GPCRs. One Sentence SummaryAnalysis of the interaction of FZD5 and DVL2 uncovers WNT-induced conformational dynamics of a WNT-FZD5-DVL2 complex.

pharmacology and toxicology↗

bioRxiv2022

Receptor levels determine binding affinity of WNT-3A to Frizzled 7 in a colorectal cancer model

WNT binding to Frizzleds (FZD) is a crucial step that leads to the initiation of signalling cascades governing multiple processes during embryonic development, stem cell regulation and adult tissue homeostasis. Recent efforts have enabled us to shed light on WNT-FZD pharmacology in overexpressed HEK293 cell systems. However, it is important to assess ligand binding at endogenous receptor levels as there might be differential binding behaviour in a native environment. Here, we focus on one FZD paralogue: FZD7, and study its interactions with WNT-3A in a CRISPR-Cas9-edited SW480 colorectal cancer model. SW480 cells were CRISPR-Cas9-edited to insert a HiBiT-tag on the N-terminus of FZD7, preserving the native signal peptide. Subsequently, these cells were used to study eGFP-WNT-3A association to endogenous and overexpressed HiBiT-FZD7 using NanoBiT/BRET to measure ligand binding and quantification of NanoBiT-emitted luminescence to assess receptor internalization. eGFP-WNT-3A bound to endogenous HiBiT-FZD7 with significantly higher kon and with lower Kd than to overexpressed receptors. Importantly, as the fluorescent probe is an agonist, experiments performed in cell lysates demonstrated that eGFP-WNT-3A/HiBiT-FZD7 binding assessment is not altered by receptor internalization. In conclusion, binding affinities of eGFP-WNT-3A to HiBiT-FZD7 decreased with increasing receptor concentrations suggesting that HiBiT-FZD7 overexpression fails to recapitulate ligand binding behaviour in a (patho-)physiologically relevant context where endogenous receptor expression levels are lower.

pharmacology and toxicology↗

bioRxiv2019

Mitochondria biogenesis in the synapse is supported by local translation

Synapses are the regions of the neuron that enable the transmission and propagation of action potentials on the cost of high energy consumption and elevated demand for mitochondrial ATP production. The rapid changes in local energetic requirements at dendritic spines imply the role of mitochondria in the maintenance of their homeostasis. Using global proteomic analysis supported with complementary experimental approaches, we show that an important pool of mitochondrial proteins is locally produced at the synapse indicating that mitochondrial biogenesis takes place locally to maintain the pool of functional mitochondria in axons and dendrites. Furthermore, we show that stimulation of synaptoneurosomes induces the local synthesis of mitochondrial proteins that are transported to the mitochondria and incorporated into the protein supercomplexes of the respiratory chain.\n\nSynopsis\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=187 SRC=\"FIGDIR/small/789164v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (47K):\norg.highwire.dtl.DTLVardef@1813d6forg.highwire.dtl.DTLVardef@1e85cd3org.highwire.dtl.DTLVardef@2656f7org.highwire.dtl.DTLVardef@1177d7d_HPS_FORMAT_FIGEXP M_FIG Mitochondria biogenesis in the synapse is supported by local translation\n\nC_FIG O_LIMitochondrial proteins represent a large pool of proteins synthesized locally at the synapse\nC_LIO_LINewly synthesized mitochondrial proteins are imported into the mitochondria and incorporated into the respiratory chain complexes\nC_LIO_LIUncoupling of mitochondria and blocking mitochondrial import inhibits incorporation of de novo synthesized proteins into the mitochondrial protein complexes\nC_LI

neuroscience↗

bioRxiv2019

A NanoBRET-based binding assay for Smoothened allows real time analysis of small-molecule ligand binding and distinction of two separate ligand binding sites for BODIPY-cyclopamine

Background and PurposeSmoothened (SMO) is a GPCR that mediates hedgehog signaling. Hedgehog binds the Patched, which in turn regulates SMO activation. Overactive SMO signaling is oncogenic and is therefore a clinically established drug target. Here, we establish a nanoluciferase bioluminescence resonance energy transfer (NanoBRET)-based ligand binding assay for SMO providing a sensitive and high throughput-compatible addition to the toolbox of GPCR pharmacologists.\n\nExperimental ApproachIn the NanoBRET-based binding assay, SMO is N terminally tagged with nanoluciferase (Nluc) and binding of BODIPY-cyclopamine is assessed by quantifying resonance energy transfer between receptor and ligand. The assay allows kinetic analysis of ligand-receptor binding in living HEK293 cells and competition binding experiments using commercially available SMO ligands (SANT-1, cyclopamine-KAAD, SAG1.3 and purmorphamine).\n\nKey ResultsThe NanoBRET binding assay for SMO is sensitive and superior to purely fluorescence-based binding assays. BODIPY-cyclopamine showed complex binding parameters suggesting separate binding sites.\n\nConclusions and ImplicationsThe NanoBRET ligand binding assay for SMO provides a fast, sensitive and reliable alternative to assess SMO ligand binding. Furthermore, this assay is sufficiently sensitive to dissect a SANT-1-sensitive and a SANT-1-insensitive cyclopamine binding site in the 7TM core, and will be important to further dissect and understand the molecular pharmacology of Class F receptors.\n\nWhat is already knownCyclopamine targets SMO as antagonist and fluorescently-labelled cyclopamine has been used for fluorescence-based binding assays for SMO. Structural analysis has suggested two binding sites on SMO, one in the receptor core and one the CRD.\n\nWhat this study addsWe established a NanoBRET-based binding assay for SMO with superior sensitivity compared to fluorescence-based assays. This assay allows distinction of two separate binding sites for BODIPY-cyclopamine on SMO in live cells in real time.\n\nWhat is the clinical significanceThe assay is a valuable complement for drug discovery efforts and will support a better understanding of Class F GPCR pharmacology.

pharmacology and toxicology↗